Genmab — Juni 2025
-
BioNTech enters PD-L1/VEGF bispecific deal with China-based Biotheus
The move is the latest in a series of deals that have found the German biotech looking to China for oncology innovation
Pharma Manufacturing (www.pharmamanufacturing.com)
-
Bristol-Myers i milliardaftale med Biontech: Køber halvpart i kræftkandidat https://proinvestor.com/investornyt/1323350/bristol-myers-i-milliardaftale-med-biontech-kober-halvpart-i-kraeftkandidat
-
Biontech købte hele Biotheus i efteråret 2024 for $800 mln - dygtige forretningsfolk. Ha r nu solgt halvdelen for bl.a. $1,5 + 2bn uofront. https://pharmaphorum.com/news/biontech-buys-biotheus-and-its-keytruda-rival-950m
-
-
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S
) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL
-01 Trial https://ir.genmab.com/news-releases/news-release-details/genmab-announces-investigational-rinatabart-sesutecan-rina-sr
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind